Aerie Pharmaceuticals Stock News

DURHAM, N.C.--(BUSINESS WIRE)--AERI 4Q & FY21 Save-the-Date

Needham & Company LLC started coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research note released on Friday morning, TipRanks reports. The firm issued a buy rating and a $22.00 price target on the stock. Several other research firms have also issued reports on AERI. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from []

In the last trading session, 2.33 million shares of the Aerie Pharmaceuticals Inc. (NASDAQ:AERI) were traded, and its beta was 0.84. Most recently the company’s share price was $8.75, and it changed around -$0.24 or -2.67% from the last close, which brings the market valuation of the company to $420.00M. AERI currently trades at a … Aerie Pharmaceuticals Inc. (NASDAQ: AERI): Would You Buy Today? Read More »

The trading price of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) closed lower on Friday, December 10, closing at $8.99, -2.92% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.06 and traded as low as $8.98. Aerie Pharmaceuticals shares last traded at $8.99, with a volume of 1,292,072 shares traded. Several analysts recently issued reports on AERI shares. HC [] The post Aerie Pharmaceuticals (NASDAQ:AERI) Stock Price Crosses Below 200-Day Moving Average of $14.06 appeared first on ETF Daily News .

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, Aerie) announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Rocklatan®/Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countri

California State Teachers Retirement System increased its position in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 5.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,406 shares of the company’s stock after acquiring an additional 3,062 shares during the quarter. California State Teachers […]

In the last trading session, 1.16 million shares of the Aerie Pharmaceuticals Inc. (NASDAQ:AERI) were traded, and its beta was 0.85. Most recently the companys share price was $9.58, and it changed around -$0.12 or -1.24% from the last close, which brings the market valuation of the company to $464.15M. AERI currently trades at a Aerie Pharmaceuticals Inc. (NASDAQ: AERI): Historical Performance And Trend Read More »

The trading price of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) closed lower on Monday, November 22, closing at $9.70, -3.39% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Aniridia Treatment Market 2021 Industry Research Report help business or organization in every sphere of trade to take better decisions, to respond the toughest business questions and reduce the risk of failure. This market study analyzes the market status, size,

State Street Corp increased its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 18.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 992,007 shares of the companys stock after buying an additional 156,548 shares during the period. State Street Corp []

Nuveen Asset Management LLC trimmed its holdings in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 90.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 428,637 shares of the company’s stock after selling 3,933,308 shares during the quarter. Nuveen Asset Management LLC owned 0.91% of Aerie […]

Northern Trust Corp grew its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 6.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 480,138 shares of the companys stock after purchasing an additional 27,377 shares during the period. Northern Trust Corp owned approximately 1.02% []

Schonfeld Strategic Advisors LLC acquired a new stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 15,395 shares of the companys stock, valued at approximately $247,000. A number of other hedge funds have also added []